| High levels of IgM against methylglyoxal-modified apolipoprotein B100 is associated with less coronary artery calcification in patients with type 2 diabetes. | |
| | |
MedLine Citation:
|
PMID: 21668821 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Objective: Advanced glycation endproducts (AGE) have been implicated in diabetic vascular complications through activation of pro-inflammatory genes. AGE-modified proteins are also targeted by the immune system resulting in the generation of AGE-specific autoantibodies, but the association of these immune responses with diabetic vasculopathy remains to be fully elucidated. The aim of this study was to determine whether antibodies against apolipoprotein B100 modified by methylglyoxal (MGO-apoB100) are associated with coronary atherosclerosis in patients with type 2 diabetes. Methods: We measured antibodies against MGO-apoB100 in plasma from 497 type 2 diabetic patients without clinical signs of cardiovascular disease. Severity of coronary disease was assessed as coronary artery calcium (CAC) imaging. Immunoglobulin (Ig)M and IgG levels recognizing MGO-apoB100 were determined by enzyme-linked immunosorbent assay. Results: Anti-MGO-apoB100 IgM antibody levels were higher in subjects with a low to moderate CAC score (≤400 Agatston units) than in subjects with a high score (>400 Agatston units; 136.8±4.4 vs. 101.6±7.4 AU (arbitrary units), P<0.0001) and in subjects demonstrating no progression of CAC during 30 months of follow-up (136.4±5.7 vs. 113.9±6.2 AU in subjects with progression, P<0.0001). Subjects with a family history of premature myocardial infarction had lower levels of anti-MGO-apoB100 IgM. Female subjects had higher levels of anti-MGO-apoB100 antibodies and lower CAC than males. Accordingly, high levels of IgM against MGO-apoB100 are associated with less-severe and a lower risk of progression of coronary disease in subjects with type 2 diabetes. Conclusions: Although conclusions regarding causal relationships based on epidemiological observations need to be made with caution, our findings suggest the possibility that anti-MGO-apoB100 IgM may be protective in diabetic vasculopathy. |
| | |
Authors:
|
Daniel Engelbertsen; Dhakshinamurthy Vijay Anand; Gunilla Nordin Fredrikson; David Hopkins; Roger Corder; Prediman K Shah; Avijit Lahiri; Jan Nilsson; Eva Bengtsson |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-6-13 |
Journal Detail:
|
Title: Journal of internal medicine Volume: - ISSN: 1365-2796 ISO Abbreviation: - Publication Date: 2011 Jun |
Date Detail:
|
Created Date: 2011-6-14 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8904841 Medline TA: J Intern Med Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2011 The Association for the Publication of the Journal of Internal Medicine. |
Affiliation:
|
Department of Clinical Sciences, Skåne University Hospital, Lund University, CRC Entrance 72, 91:12, 205 02 Malmö, Sweden Cardiac Imaging and Research Centre, Wellington Hospital, London, UK Department of Biomedical Laboratory Science and Technology, Malmö University, Malmö, Sweden Department of Diabetic Medicine, King's College Hospital, London, UK William Harvey Research Institute, London, UK Atherosclerosis Research Center and Division of Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA, USA David Geffen School of Medicine, UCLA School of Medicine, Los Angeles, CA, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Lifetime dog and cat exposure and dog- and cat-specific sensitization at age 18 years.
Next Document: Chemotherapy Only for Localized Hodgkin Lymphoma.